Shares of Aurobindo Pharma Ltd have perked up by Rs 8.55 to Rs 139.20 (face value Re 1) on the BSE after the company informed that the USFDA has lifted the import alert for non-sterile products manufactured at one of its units in Hyderabad.

Quoting USFDA Web site, the company said that the import alert for non-sterile products produced at its unit-VI cephalosporin facility in Hyderabad I has been lifted, enabling resumption of exports of nine products to the US market.

Before the import alert was issued in February 2011, the unit had annual US sales of $33 million for the above mentioned products, APL said.

(This article was published on March 28, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.